Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

FOXO4-DRI.

Research draft

FOXO4-DRI is an experimental senolytic peptide.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

FOXO4-DRI is an experimental senolytic peptide.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It is designed to disrupt FOXO4-p53 interactions and promote death of selected senescent cells.

Human research

A therapeutic human evidence base was not established.

Preclinical & other research

Cell and aged-mouse studies examined senescence-related endpoints; human-cell experiments are still preclinical.

Safety & unknowns

Selective cell removal and longer-term tissue effects are not characterised sufficiently in people.

Regulatory status

Preclinical research compound, not an established rejuvenation treatment.

Reported use & evidence

Research profile draft

The supplied FOXO4-DRI profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds